Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Diabetes Care

• Publication date

  2014-12-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/dc14-1952PMID 25519448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers

  2016cited by this paper
• Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial

  2014cited by this paper
• Age‐dependent decline of β‐cell function in type 1 diabetes after diagnosis: a multi‐centre longitudinal study

  2014cited by this paper
• Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study

  2014cited by this paper
• Standards of Medical Care in Diabetes—2014

  2013cited by this paper
• The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells

  2013cited by this paper
• Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents.

  2013cited by this paper
• The clinical utility of C-peptide measurement in the care of patients with diabetes

  2013cited by this paper
• Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study

  2012cited by this paper
• Fall in C-Peptide During First 2 Years From Diagnosis

  2012cited by this paper
• Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3).

  2012cited by this paper
• The T1D Exchange clinic registry.

  2012cited by this paper
• Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay

  2012cited by this paper
• Standards of Medical Care in Diabetes—2012

  2011cited by this paper
• Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study

  2010cited by this paper
• Preservation of β-Cell Function in Autoantibody-Positive Youth With Diabetes

  2009cited by this paper
• C‐peptide in the natural history of type 1 diabetes

  2009cited by this paper
• Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes

  2008cited by this paper
• Standards of Medical Care in Diabetes: Response to Power

  2006cited by this paper
• C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

  2004cited by this paper
• Diabetes Therapeutics News

  2003cited by this paper

• Ketoacidosis at childhood type 1 diabetes onset negatively affects residual beta-cell functions during the first year after diagnosis

  2026influential citation
• Quantification of D-Amino Acids in Type 1 Diabetes-Affected Human Serum.

  2026cites this paper
• Identification of a type 1 diabetes–associated T cell receptor repertoire signature from the human peripheral blood

  2026cites this paper
• Reassessing diabetes type with C peptide and feasibility of transitioning therapy from insulin to non-insulin therapy

  2026cites this paper
• Effect of Residual Insulin Secretion on Glycaemic Control Among Young Cameroonian Individuals With Type 1 Diabetes

  2026cites this paper
• The partial clinical remission phase of type 1 diabetes: early-onset dyslipidemia, long-term complications, and disease-modifying therapies.

  2025cites this paper
• Type 1 diabetes presenting in adults: Trends, diagnostic challenges and unique features

  2025cites this paper
• Understanding Diabetes Mellitus: Complications, Novel targets and Advancement in Treatment Strategies

  2025cites this paper
• Integrating Neural Differential Forecasting with Safe Reinforcement Learning for Blood Glucose Regulation

  2025influential citation
• Duration of type 1 diabetes and glycaemic control in adults: A nonlinear relationship

  2025cites this paper
• Preparing to Meet the Needs of a Growing Older Adult Population with Type 1 Diabetes: A Narrative Review.

  2025cites this paper
• Target Discovery to Diabetes Therapy - TXNIP From Bench to Bedside with NIDDK.

  2025cites this paper
• Pubertal stage significantly and independently impacts C-peptide levels at type 1 diabetes diagnosis along with body mass index and age

  2025cites this paper
• LADA: A case for starting insulin therapy at diagnosis

  2025cites this paper
• Residual insulin secretion in long‐standing type 1 diabetes

  2025cites this paper
• Adult-onset type 1 diabetes: early detection, differential diagnosis, and emerging disease-modifying therapies.

  2025cites this paper
• Predicting stimulated C-peptide in type 1 diabetes using machine learning: a web-based tool from the T1D exchange registry.

  2025cites this paper
• Comparative Analysis of Islet Auto-Transplantation Outcome Classification Systems: Evaluating Concordance, Feasibility, and a Data-Driven Approach

  2025cites this paper
• The Heterogeneity of Type 1 Diabetes: Implications for Pathogenesis, Prevention, and Treatment—2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum

  2025cites this paper
• The role of GLP1 receptor agonists in adult-onset type 1 diabetes mellitus

  2025cites this paper
• New Perspectives in Studying Type 1 Diabetes Susceptibility Biomarkers

  2025cites this paper
• The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment—2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum

  2025cites this paper
• Global, regional and national burdens of chronic kidney disease due to T1DM and T2DM among adolescents and young adults aged 10-35 years from 1990-2021: A trend analysis based on the global burden of disease study 2021.

  2025cites this paper
• The Heterogeneity of Type 1 Diabetes: Implications for Pathogenesis, Prevention, and Treatment—2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum

  2025cites this paper
• Preserved C-peptide is common and associated with higher time in range in Chinese type 1 diabetes

  2024cites this paper
• The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults

  2024cites this paper
• An online tool using clinical factors to estimate the probability of partial clinical remission of adult-onset Type 1 diabetes.

  2024cites this paper
• Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS

  2024cites this paper
• Utility of Fasting C-Peptide for the Diagnostic Differentiation of Patients with Type 1, Type 2 Diabetes, MODY, and LADA

  2024cites this paper
• Comparison of an oral mixed meal plus arginine and intravenous glucose, GLP-1 plus arginine to unmask residual islet function in longstanding type 1 diabetes

  2024cites this paper
• Untangling the genetics of beta cell dysfunction and death in type 1 diabetes

  2024cites this paper
• The epidemiology of type 1 diabetes mellitus in older adults

  2024cites this paper
• Hat, hosszú távon gondozott, 50 év feletti betegségtartamú 1-es típusú diabéteszes személy hossz- és keresztmetszeti elemzése

  2024cites this paper
• The relationship between residual insulin secretion and subclinical cardiovascular risk indices in young adults with type 1 diabetes.

  2024cites this paper
• Effect of fenofibrate on residual beta cell function in adults and adolescents with newly diagnosed type 1 diabetes: a randomised clinical trial

  2024cites this paper
• Metabolic impact of residual C-peptide secretion in type 1 diabetes mellitus

  2024cites this paper
• Modern insulin treatment for type 2 diabetes

  2024cites this paper
• The Human Pancreas in Type 1 Diabetes: Lessons Learned from the Network of Pancreatic Organ Donors with Diabetes.

  2024cites this paper
• Autoantibodies as important biomarkers in early diagnosis of type-1 diabetes

  2024cites this paper
• C-Peptid als Surrogatparameter einer residualen Beta-Zellfunktion bei Typ-1-Diabetes und ihre mögliche klinische Bedeutung

  2024cites this paper
• Unraveling Verapamil’s Multidimensional Role in Diabetes Therapy: From β-Cell Regeneration to Cholecystokinin Induction in Zebrafish and MIN6 Cell-Line Models

  2024cites this paper
• Relationship Between C-Peptide Levels, Clinical Features, and Serum Data in a Brazilian Type 1 Diabetes Population with Large Variations in Genomic Ancestry

  2024cites this paper
• Genetics of C-Peptide and Age at Diagnosis in Type 1 Diabetes

  2024cites this paper
• Understanding Insulin in the Age of Precision Medicine and Big Data: Under-Explored Nature of Genomics

  2023cites this paper
• Clinical Application of Umbilical Cord Mesenchymal Stem Cells Preserves β-cells in Type 1 Diabetes

  2023cites this paper
• Diabetic ketosis vs ketoacidosis as initial presentation of pediatric type 1 diabetes mellitus. Associated features and rate of progression during the first two years after diagnosis.

  2023cites this paper
• Quantifying beta cell function in the preclinical stages of type 1 diabetes

  2023cites this paper
• The challenges of identifying and studying type 1 diabetes in adults

  2023cites this paper
• Residual insulin secretion in individuals with type 1 diabetes in Finland: longitudinal and cross-sectional analyses.

  2023cites this paper
• Age of Diagnosis Does Not Alter the Presentation or Progression of Robustly Defined Adult-Onset Type 1 Diabetes.

  2023cites this paper
• Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023).

  2023cites this paper
• Tip 1 Diabetes Mellitus Tanılı Hastalarda Poliglandüler Otoimmün Sendrom Sıklığının Tespiti ve Diyabetin Prognoz ve Komplikasyonları ile İlişkisinin Araştırılması

  2023cites this paper
• Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes.

  2023cites this paper
• Insights on C-peptide in diabetes

  2023cites this paper
• Islet autoantibodies and residual beta-cell function in children with type 1 diabetes depending on age of manifestation

  2023cites this paper
• Changes in C-Peptide Values in Children with Type 1 Diabetes - a Three-Year Study.

  2023cites this paper
• Short-term fasting lowers glucagon levels under euglycemic and hypoglycemic conditions in healthy humans

  2023cites this paper
• Residual β-cell function in Brazilian Type 1 diabetes after 3 years of diagnosis: prevalence and association with low presence of nephropathy

  2023cites this paper
• Urinary c‐peptide creatinine ratio (UCPCR) as a predictor of coronary artery disease in type 1 diabetes mellitus

  2023cites this paper
• Incident cardiovascular-kidney disease, diabetic ketoacidosis, hypoglycaemia and mortality in adult-onset type 1 diabetes: a population-based retrospective cohort study in Hong Kong

  2023cites this paper
• Islet cells in human type 1 diabetes: from recent advances to novel therapies – a symposium-based roadmap for future research

  2023cites this paper
• Diabetes Study of Children of Diverse Ethnicity and Race: Study design

  2023influential citation
• Prolonged clinical remission of type 1 diabetes sustained by calcifediol and low-dose basal insulin: a case report.

  2023cites this paper
• The MHC Class II Antigen-Processing and Presentation Pathway Is Dysregulated in Type 1 Diabetes.

  2023cites this paper
• A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes

  2022cites this paper
• The Theory of Hyperlipidemic Memory of Type 1 Diabetes

  2022cites this paper
• The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes

  2022cites this paper
• Preserved C-peptide secretion is associated with higher time in range (TIR) on intermittently scanned continuous glucose monitoring in Chinese adults with type 1 diabetes

  2022cites this paper
• New therapeutic approaches for type 1 diabetes: Disease-modifying therapies

  2022cites this paper
• Continuous Adaptation with Online Meta-Learning for Non-Stationary Target Regression Tasks

  2022cites this paper
• Evaluating T cell responses prior to the onset of type 1 diabetes

  2022cites this paper
• Restoring tolerance to β-cells in Type 1 diabetes: Current and emerging strategies.

  2022cites this paper
• Fasting and meal‐stimulated serum C‐peptide in long‐standing type 1 diabetes mellitus

  2022cites this paper
• High Residual β-cell Function in Chinese Patients with Autoimmune Type 1 Diabetes.

  2022cites this paper
• Epidemiology of Type 1 Diabetes

  2022cites this paper
• Precision medicine in type 1 diabetes

  2022cites this paper
• Verapamil and Its Role in Diabetes

  2022cites this paper
• Diabetes Mellitus

  2022cites this paper
• Sphingomyelin profiling in patients with diabetes could be potentially useful as differential diagnostics biomarker: A pilot study.

  2022cites this paper
• Multiple endocrine neoplasia type 2 and autoimmune polyendocrine syndromes (type 1 diabetes mellitus and Graves' disease) in a 16-year-old male with Kabuki syndrome.

  2022cites this paper
• C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective

  2022cites this paper
• Birth Order, Caesarean Section, or Daycare Attendance in Relation to Child- and Adult-Onset Type 1 Diabetes: Results from the German National Cohort

  2022cites this paper
• Psychosocial Needs for Newly Diagnosed Youth with Type 1 Diabetes and Their Families

  2022cites this paper
• Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration

  2022cites this paper
• Exocrine and Endocrine Inflammation Increases Cellular Replication in the Pancreatic Duct Compartment in Type 1 Diabetes

  2022cites this paper
• Partial Clinical Remission of Type 1 Diabetes: The Need for an Integrated Functional Definition Based on Insulin-Dose Adjusted A1c and Insulin Sensitivity Score

  2022cites this paper
• C-peptide levels and the prevalence of islets autoantibodies in children with type 1 diabetes mellitus with different duration of the disease

  2022cites this paper
• Glucose-induced insulin secretion in isolated human islets: Does it truly reflect β-cell function in vivo?

  2021cites this paper
• Residual β-cell function after 10 years of autoimmune type 1 diabetes: prevalence, possible determinants, and implications for metabolism

  2021influential citation
• Altered β-Cell Prohormone Processing and Secretion in Type 1 Diabetes

  2021cites this paper
• Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes

  2021cites this paper
• Long-term β-cells autoimmune destruction markers persistence and residual C-peptide secretion in type 1 diabetes mellitus

  2021cites this paper
• Autoantibody-Negative Type 1 Diabetes: A Neglected Subtype.

  2021cites this paper
• Three‐phasic pattern of C‐peptide decline in type 1 diabetes patients with partial remission

  2021cites this paper
• A Study of Residual C-Peptide Level (Fasting and Post OGTT) in Type –1 Diabetes Population & It’s Correlation with duration of Diabetes and Antibody Status in a Tertiary Care Centre in Eastern India

  2021influential citation
• “Can Home-Based High Intensity Interval Training Improve Post Exercise Glycaemic Control in People with Type 1 diabetes?”

  2021cites this paper
• Adult-Onset Type 1 Diabetes: Current Understanding and Challenges

  2021cites this paper
• Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia.

  2021cites this paper
• The many faces of islet antigen‐specific CD8 T cells: clues to clinical outcome in type 1 diabetes

  2021cites this paper
• C-peptide and residual β-cell function in pediatric diabetes – state of the art

  2021cites this paper